The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Subscribe To Our Newsletter & Stay Updated